HIGHLIGHTS
- What: Pseudohyperaldosteronism for tetrazole antifungals using the H295R cell model and targeted steroid quantification A first goal of this work was to evaluate the risk of pseudohyperaldosteronism for tetrazole antifungals. Complete inhibition after Odermatt, 2021), the results from this study were compared with those from earlier results on triazoles (Jäger M. et_al, 2023).
- Who: Amit V. Pandey and collaborators from the University of Bern, Switzerland have published the article: Assessment of the potential risk of oteseconazole and two other tetrazole antifungals to inhibit adrenal steroidogenesis and peripheral metabolism of corticosteroids, in the Journal: (JOURNAL . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.